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Abstract
Background: Several lines of evidence indicate that immature oocyte retrieval and subsequent in vitro maturation (IVM)
without ovarian stimulation may be a reliable option in assisted reproductive technologies (ART). However, few outcome
data are available for children born following this technique.
Objective: We assessed height and weight development of French children conceived after IVM.
Methods: All children conceived after IVM at Antoine Beclere Hospital (Clamart, France) and born between June 2003 and
October 2008 (n= 38) were included in a prospective cohort study and compared with a control group of children
conceived by ICSI without IVM, matched for maternal age, gestational age and singleton/twin pregnancies. Follow-up
included clinical examination at one year and a questionnaire completed by parents when the children were two years old
(97% follow-up rate).
Results: No statistical differences between IVM and control groups were found for boys. Mean weight, height and head
circumference at birth were significantly greater for IVM than for ICSI girls (3.236 kg vs 2.701 kg (p= 0.03); 49 cm vs 47 cm
(p= 0.01) and 34 cm vs 33 cm (p= 0.04), respectively). At one year, IVM girls remained heavier (mean weight 10.2 kg vs
8.6 kg (p= 0.001)) and taller (76 cm vs 73 cm (p= 0.03)), and there was a two-point difference in BMI between the two
groups of girls (18 vs 16 (p= 0.01)).
Conclusion: Our results in girls born after IVM should be interpreted with caution. It remains unclear whether the observed
sexual dimorphism is due to IVM technology or to maternal characteristics such as underlying infertility in patients with
polycystic ovary syndrome (PCOS). Further monitoring of the outcomes of these infants is required.
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Introduction
In last decades, in vitro fertilisation (IVF) has become established
as a reliable therapeutic option for overcoming infertility, resulting
in the birth of more than four million children. Modern IVF
protocols use high doses of exogenous gonadotropins to generate
mature follicles. However, some women are extremely sensitive to
controlled ovarian stimulation and are at risk of developing
ovarian hyperstimulation syndrome (OHSS). The retrieval of
immature oocytes from small antral follicles and their subsequent
in vitro maturation (IVM) has therefore been proposed as an
alternative option, to avoid the possible side effects of exogenous
gonadotropin administration. Therefore, patients suffering from
polycystic ovarian syndrome (PCOS) currently remain the main
candidates for such a treatment [1]. However, the indications for
IVM treatment have remarkably expanded, and now include poor
responders to controlled ovarian hyperstimulation, and oocyte
donation. The results of most studies investigating the health risks
of children conceived after ICSI are reassuring [2] [3], but very
little is known about the outcome of infants born after IVM,
because this technique is much more recent [4]. Indeed, most
studies reporting the outcome of infants conceived after IVM
included only small numbers of patients, without controls [5] [6]
[7] [8] [9]. However, theoretical concerns have been raised
concerning the safety of IVM, including the risk of chromosomal
abnormalities in the resulting embryos [10], the possible impact on
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the expression of imprinting genes [11] [12] and more recently a
higher birth weight of IVM babies compared to ICSI babies [13].
To-date, this difference in birth weight has not been studied
according to sex.
The objective of this study was to assess height and weight
developments of a French cohort of children conceived after IVM.
Materials and Methods
All infants conceived after IVM at Antoine Beclere Hospital
(Clamart, France) and born between June 2003 and October 2008
(‘‘IVM group’’, n=38) were included in a prospective cohort
study. All mothers of these infants had PCOS. PCOS was
characterised by endocrine disorders, with oligo- or anovulation,
hyperandrogenism and polycystic ovaries.
These infants were compared with a control group of children
conceived after ICSI without IVM (control group, mostly born to
couples in whom the man displayed severe infertility) at the same
centre and born between 2002 and 2008, matched for maternal
age (#35, .35), gestational age (,37, $37 WG) and singleton or
twin pregnancies.
IVM and control embryos were generated during the study
period at the same perinatal centre, by the same clinical and
biological teams, and follow-up was undertaken by the same two
paediatricians for both groups of patients.
Definition of Treatments
IVM group. IVM was performed only in patients diagnosed
with PCOS. In all cases the IVM protocol was performed as
previously described [14]. Patients underwent a baseline ultra-
sound scan between days 2 and 4 of either a natural menstrual
cycle, or, if amenorrheic, after withdrawal bleeding induced by
progesterone treatment. to determine the number and size of
antral follicles and endometrial thickness. The same evaluation
was repeated between days 6 and 8 and when endometrial
thickness was $6 mm, patients received 10,000 IU hCG i.m.
Oocyte cumulus complexes (OCCs) were retrieved 35–36 hours
after hCG administration, by trans-vaginal ultrasound-guided
aspiration. Follicular fluids were collected in tubes containing 5 ml
of prewarmed heparinised saline (100 ml in 250 ml NaCl). OCCs
were washed in IVF medium (Origio, France) and matured in
1 ml of IVM medium (Origio, France) supplemented with 20%
heat-inactivated serum from the patient, 0.75 IU/ml follicle-
stimulating hormone (FSH) and 0.75 IU/ml luteinising hormone
(LH) for 24 h. The oocytes were then denuded of cumulus cells
with hyaluronidase and mechanical pipetting and their maturity
was checked. Matured oocytes were inseminated by ICSI, with the
partner’s spermatozoa.
Control group. Women underwent controlled ovarian hy-
perstimulation according to long agonist or antagonist protocols.
In the long agonist protocol, patients received a time-release
GnRH agonist (GnRH-a) on cycle day 2. Three weeks later,
complete pituitary desensitisation was confirmed by the detection
of low serum oestradiol (E2) and gonadotropin concentrations.
Thereafter, recombinant FSH administration was initiated.
Patients undergoing an antagonist protocol received micronised
17b-E2 oral tablets from day 20 of the cycle at treatment initiation
until day 2 of the next cycle. On the first day of 17b-E2
discontinuation (cycle day 3), recombinant FSH administration
was started. In both protocols, doses were adjusted according to
the usual follicular maturation criteria. In antagonist protocols,
GnRH antagonist was administered daily from day 6. We
administered hCG (10,000 IU, i.m) when the follicles exceeded
17 mm in diameter and E2 concentration in the mature follicle
exceeded 300 pg/ml. Oocytes were retrieved 36 hours after hCG
administration, by trans-vaginal ultrasound-guided aspiration, and
were inseminated by ICSI with the partner’s spermatozoa.
IVM and control groups. Fertilisation was assessed 17–19
hours after insemination, by checking for the appearance of two
distinct pronuclei and two polar bodies. The zygotes were cultured
in ISM1–ISM2 Medium (Origio, France). Embryos development
was assessed on day 2 (41–43 h) and on day 3 (65–67 h) after
insemination, by evaluating the regularity of blastomeres, the
percentage and pattern of anucleate fragments and the dysmor-
phic characteristics of the embryos. The best embryos were
transferred on day 2 or day 3 after ICSI.
We collected the following data for the mother’s characteristics:
maternal age, parity, smoking status, pre-pregnancy body mass
index (BMI defined as the ratio (weight (kg)/height2 (m2)). These
data were extracted from hospital medical records. We also
collected maternal information about infertility treatment, delivery
and health of the infant at birth.
Maternal age was considered as a quantitative variable; tobacco
use was considered as a dichotomous variable, with the categories
‘‘smoker’’ and ‘‘non-smoker’’ during pregnancy.
All women had undergone screening for gestational diabetes by
a two-step approach [15]. An initial screening was performed
between 24 and 28 weeks of gestation, by determining the plasma
or serum concentration of glucose, one hour after a oral loading
with 50 g of glucose (glucose challenge test (GCT)). In women
whose glucose concentration exceeding the threshold value for the
GCT (7.8 mmol/l), a diagnostic oral glucose tolerance test
(OGTT) was performed. for which the diagnostic criteria for the
OGTT (oral loading with 100 g glucose) were as follows:
gestational diabetes mellitus was diagnosed if two or more of the
blood glucose concentrations obtained reached or exceeded the
threshold values of 5.3 mmol/l after an overnight fast,
10.0 mmol/l after 1 hour, 8.6 mmol/l after 2 hours and
7.8 mmol/l after 3 hours.
We recorded the following characteristics of the neonates: sex,
birth weight, height, head circumference, APGAR score. All these
data were obtained from hospital records. Follow-up involved
clinical examination at the age of one year and a questionnaire
completed by the parents when the child was two years old.
Parents provided data on weight, height and head circumference
based on the results of the clinical examination conducted at 2
years of age and reported in their child’s health booklet.
This study was approved by the C.C.T.I.R.S. (Comite´
consultatif sur le traitement de l’information en matie`re de
recherche – National consultative committee on the treatment of
information for research) and registered under number ‘‘06.192’’.
Parents were told about the study by medical staff during the
pregnancy and were provided with written information. Written
informed consent was collected from the parents for themselves
and on behalf of their children involved in the study by the
paediatrician during the clinical examination at the age of one
year.
IVM and ICSI groups were compared using Student’s t tests for
quantitative variables and chi-squared tests for qualitative
variables. Non-parametric Kruskal-Wallis tests were used to
compare IVM and ICSI children by sex. Statistical tests were
two-tailed, with p,0.05 considered significant.
Results
The study included a total of 76 infants born from 68
pregnancies (60 singletons and 8 sets of twins); 38 infants were
born following IVM, and the control group also included 38
Height and Weight Development of IVM Children
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infants. The characteristics of mothers and pregnancies did not
differ significantly between groups (Table 1).
In both groups, mean maternal age was 32.9 years, mean
gestational age was 39 weeks and 88% of pregnancies were
singletons.
Overall, 11.8% of mothers in the IVM group were diagnosed
with gestational diabetes, versus only 5.9% in the control group
(p=0.39) and 35.3% of IVM infants were born after Caesarean
section, versus only 18.8% in the control group. However, none of
these differences was significant. In addition, it is noticeable that
maternal characteristics were comparable among women having
given birth to boys or girls (data not shown).
The characteristics of infants at birth did not significantly differ
between groups. However, the mean weight tended to be higher in
the IVM group than in controls (3,120 g vs 2,967 g, p= 0.41)
(Table 2).
Findings at one and two years are displayed in Table 3. The
mean weight of the IVM group infants was significantly higher
than that of the control group (10.3 kg vs 9.2 kg, p,0.001). IVM
infants were also significantly taller than controls (76.8 cm vs
74.4 cm, p,0.01) and their BMI was greater (17.5 vs 16.5,
p = 0.01).
At the age of two years, IVM children were significantly heavier
than controls (12.9 kg vs 12.0 kg, p,0.01), and their BMI was
greater (17.0 vs15.9, p,0.01. However, there was no significant
difference between groups in terms of height or head circumfer-
ence.
Weight, height, head circumference and BMI were then studied
separately for boys and girls at birth, and at one and two years of
age (Table 4).
IVM girls were heavier than controls girls at birth, with a mean
weight of 3,236 g vs 2,701 g respectively (p=0.03). Similarly, birth
heights of IVM girls were greater than those of control girls
(49.3 cm vs 46.9 cm (p=0.01)) and they also had a larger head
circumference (34.1 cm vs 32.9 cm (p=0.04)).
At the age of one year, IVM girls were still heavier (10.2 kg vs
8.6 kg (p=0.001)), and taller (75.9 cm vs 72.7 cm (p=0.03)) than
the control girls and there was a significant difference in BMI (17.6
vs 16.2 (p = 0.01)) between both groups of girls. However, the
difference in head circumference was no longer significant.
At the age of two years, the sex effect remained, with IVM girls
still heavier than control girls (12.9 kg vs 11.6 kg (p=0.02)), and
with a greater BMI (17.2 vs 15.8 (p = 0.02)).
Regarding boys, no significant difference was underlined
between the two groups for weight, height and head circumference
either at birth, at one or two years of age.
Discussion
We found no significant differences between IVM and control
groups, in terms of maternal and obstetric characteristics.
However, we highlighted a sexual dimorphism. Unlike boys,
IVM girls had a greater weight, height and head circumference at
birth than did control girls (ICSI). This difference between sexes
was maintained over time, with IVM girls having a greater BMI
than control girls at the ages of one and two years.
The follow-up rate was excellent, with 97% of the families
completing the questionnaire when their children were two years
old, thereby limiting selection bias.
Table 1. Characteristics of Mothers and Pregnancies N= 68.
IVM Control p
(n =34) (n =34)
Maternal Age (years). Mean (sd) 32.9 (3.3) 32.9 (3.3)
Maternal BMI 22.6 (5.6) 22.3 (3.3) 0.78
Primipara (%) 83.3 79.3 0.69
Non-smoker (%) 100.0 91.2 0.09
Gestational Diabetes (%) 11.8 5.9 0.39
Fresh embryo transfer (%) 97.0 97.0 0.90
Gestational age (weeks). mean (sd) 39.1 (3.3) 39.3 (2.1) 0.74
Number of embryos transferred (%)
1 5.8 5.9
2 67.7 67.7
3 26.5 26.5
Singletons (%) 88.2 88.2
Delivery (%) 0.13
Spontaneous delivery 50.0 73.6
Induced delivery 35.3 17.6
C-section before labor 14.7 8.8
Type of delivery (%) 0.13
Vaginal 64.7 81.2
C-section 35.3 18.8
Control : ICSI without IVM.
doi:10.1371/journal.pone.0089713.t001
Table 2. Characteristics of Infants at birth.
N=76
IVM control P
(n=38) (n=38)
Sex (% boys) 57.9 60.5 0.81
Birthweight (g). Mean (sd) 3119.5 (871.6) 2966.6 (742.7) 0.41
Height (cm). Mean (sd) 48.6 (4.7) 47.8 (3.5) 0.42
Head circumference (cm). Mean (sd) 33.6 (2.7) 33.7 (2.0) 0.86
Apgar $7 at 5 min (%) 91.7 97.2 0.30
doi:10.1371/journal.pone.0089713.t002
Table 3. IVM & ICSI Outcomes at 1 year and two years.
IVM Control p
At 1 year (n =38) (n=38)
Weight (kg) Mean (sd) 10.3 (1.1) 9.2 (1.4) 0.0002
Height (cm). Mean (sd). 76.8 (4.0) 74.4 (3.2) 0.006
Head circumference (cm). Mean (sd) 46.9 (1.4) 46.4 (1.3) 0.08
BMI 17.5 16.6 0.01
At 2 years (n =37) (n=37)
Weight (kg) at 2 year. Mean (sd) 12.9 (1.4) 12.0 (1.3) 0.004
Height (cm). Mean (sd). 87.2 (3.7) 86.8 (2.9) 0.62
Head circumference (cm). Mean (sd) 48.8 (1.6) 49.0 (2.3) 0.73
BMI 17.0 15.9 0.002
doi:10.1371/journal.pone.0089713.t003
Height and Weight Development of IVM Children
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The control group included infants born after ICSI. This choice
of ICSI controls can be discussed. Most previous studies focusing
on children conceived through IVM did not use control group [5],
[6], [7]. In addition, comparative investigations [8], [9] mainly
included infants conceived spontaneously. Since in vitro matured
oocytes are fertilised by ICSI in the IVM protocol, the choice of an
ICSI control group instead of natural pregnancies enabled a
specific focus on the IVM technique itself. Furthermore the
prevailing policy in our centre was to exclusively propose IVM to
all women displaying PCOS criteria. Therefore it was not possible
to recruit PCOS women having undergone ICSI after controlled
ovarian hyperstimulation. Because of this, the results of the present
investigation do not enable to precisely determine which part of
the observed differences is due to the technique itself and to the
underlying PCOS.
The sample size of this study (16 girls and 22 boys born after
IVM and 15 girls and 23 boys in the control group) though
limited, is similar to those of other studies [5], [8]. The statistical
power of comparisons within sex was thus limited too. However,
this limited power cannot induce a spurious significant difference
between IVM and controls among girls, and it is important to
point out that, with a similar sample size, differences were not
significant among boys.
Women in the IVM group had a higher frequency of gestational
diabetes (11.8% vs 5.9% (p=0.39)), a higher frequency of
Caesarean section (35.3% vs 18.8% (p=0.3)), although neither
of these differences were significant. Maternal mean BMIs were
very similar in both groups (22.4 vs 22.1 kg/m2 (p=0.78)).
Soderstrom-Antilla et al [7] reported obstetric and perinatal
outcomes in 43 women who had given birth to 46 infants after
IVM. They reported a rate of gestational diabetes of 7% and a rate
of delivery by Caesarean section of 35%. More recently, Buckett
et al. [9] reported a significantly higher rate of gestational diabetes
in women who became pregnant after IVM (17%) than in patients
conceiving by ICSI (10%). This difference probably reflects the
fact that all patients are suffering from PCOS, a risk factor for
gestational diabetes, in the IVM population.
Indeed, previous studies have reported a higher risk of adverse
pregnancy outcomes in the PCOS population [16], [17].
Boosma et al. [16] recently showed, in a meta-analysis, that
women with PCOS were at higher risk of developing gestational
diabetes, pregnancy-induced hypertension, preeclampsia and
preterm births. More recently, Roos et al. [17] highlighted, in a
Table 4. IVM & ICSI weight, height and cranial circumference according to sex.
NT=76
Boys Girls
IVM ICSI p* IVM ICSI p*
22 23 16 15
Birth
Weight (g) at birth. mean (sd) 3034.5 (1015.5) 3139.6 (781.6) 0.80 3236.3 (636.4) 2701.3 (611.1) 0.03
range 540–4350 1020–4210 1880–4190 1580–3510
Height (cm) at birth. mean (sd) 48.0 (5.8) 48.4 (4) 0.79 49.3 (2.4) 46.9 (2.5) 0.01
range 28–52 38–54 44–53 43–50
Head circumference (cm) at birth. mean (sd) 33.3 (3.2) 34.3 (2.1) 0.21 34.1 (1.7) 32.9 (1.8) 0.04
range 22–37 29–37 30–37 30–37
1 year
Weight (kg) at 1 year. mean (sd) 10.4 (1.1) 9.6 (1.4) 0.12 10.2 (1.2) 8.6 (1.0) ,1023
range 8.1–12.5 7.5–12.2 8.2–12.9 7.1–10.8
Height (cm) at 1 year. mean (sd) 77.4 (4.0) 75.6 (3.1) 0.10 75.9 (3.9) 72.7 (2.5) 0.03
range 70–85 70–80 71–84 68–77
BMI at 1 year. mean (sd) 17.4 (1.0) 16.8 (1.9) 0.22 17.6 (1.6) 16.2 (1.2) 0.01
range 15.8–19.1 13.7–20.5 14.9–20.8 14.4–18.5
Head circumference (cm) at 1 year. mean (sd) 47.2 (1.4) 46.6 (1.2) 0.12 46.6 (1.4) 46.1 (1.3) 0.19
range 44–49.5 44–49 43–49 44–49
2 years
Weight (kg) at 2 years. mean (sd) 12.9 (1.3) 12.3 (1.3) 0.26 12.9 (1.5) 11.6 (1.2) 0.02
range 11.3–16.0 9.8–14.4 10.5–15.0 9.3–13.2
Height (cm) at 2 years. mean (sd) 87.8 (3.9) 87.6 (2.3) 0.76 86.5 (3.3) 85.7 (3.3) 0.90
range 76–95 83–91 80–92 76–89
BMI at 2 years. mean (sd) 16.8 (1.8) 16.0 (1.5) 0.27 17.2 (1.7) 15.8 (0.9) 0.02
range 13.6–21.1 12.1–18.2 15.1–20.3 14.5–17.2
Head circumference (cm) at 2 years. mean (sd) 49.3 (1.3) 48.6 (1.7) 0.32 48.2 (1.8) 49.4 (2.9) 0.45
range 47–51 43–51 44–50 46–58
*Comparison between IVM and ICSI. Kruskal Wallis test.
doi:10.1371/journal.pone.0089713.t004
Height and Weight Development of IVM Children
PLOS ONE | www.plosone.org 4 February 2014 | Volume 9 | Issue 2 | e89713
population-based cohort study on singleton births based on the
Swedish medical register between 1998–2007, that PCOS was also
associated with preeclampsia, very preterm birth and an increase,
by a factor of more than two, in the risk of gestational diabetes.
Women with PCOS also had a higher risk of emergency and
elective Caesarean section. The authors concluded that these risks
of adverse pregnancy and birth outcome could not be explained by
the reproductive technology used.
Even though the difference observed was not statistically
significant (p = 0.41) we found a trend of slightly greater birth
weight in the IVM group. This result is consistent with the findings
of previous studies on children born from ICSI and IVM
treatment [13] and children born after IVM and spontaneously
conceived singletons [9].
However, one of the striking findings of our study was the
difference in birth-weight, height and head circumference between
IVM and control girls, but not in boys. This difference between
sexes was maintained over time even after adjusting for gestational
age and the exact age at examination.
No study of children born following IVM has, to our knowledge,
ever investigated the outcome of these children according to sex
[5] [6] [7] [8] [9]. We wondered whether the greater weight of
IVM girls could be due to different distributions of singletons and
multiples between the IVM and ICSI groups. Data showed that
81% of IVM girls were singletons compared to 67% of ICSI girls.
After excluding twins, the difference between sexes remained.
Our results for IVM girls may be accounted for by adverse
effects of the IVM technique, leading to sexual dimorphism and
foetal programming process. However, they may also be
accounted for by maternal characteristics.
Indeed, the frequency of gestational diabetes (with foetal
hyperinsulinism) was higher in IVM than in control mothers.
However, the frequency of diabetes is not sufficient in itself to
account for the observed differences, particularly given the
maintenance of these differences over time, even after the
exclusion of diabetic mothers. Furthermore, gestational diabetes
cannot account for the detection of these differences only in girls.
PCOS of mothers treated by IVM may also play a role. Roos
et al. [17] reported that infants born to mothers with PCOS were
more frequently large for gestational age, but other studies did not
confirm this increase in the risk of macrosomia [18] [19] [20]. In a
meta-analysis of pregnancy outcomes in women with PCOS,
Boomsma et al. [16] did not confirm that infants born to mothers
with PCOS had a greater birth weight. Indeed, in another study
[21] the risk of being born small for gestational age was actually
found to be greater in babies of mothers with PCOS. Beyond the
potential impact of PCOS on growth, it is possible that certain
treatments given to PCOS women during pregnancy may affect
growth of the child [22]. These conflicting findings highlight the
current lack of consensus regarding the impact of PCOS on birth
weight.
It has been suggested that the higher level of exposure of males
to prenatal androgens promotes foetal growth. Thus, as women
with PCOS have higher plasma testosterone concentrations than
other women, IVM girls may have been exposed to higher levels of
testosterone, affecting their foetal growth and their birth weight, in
particular.
Barry et al. [23] studied umbilical vein testosterone concentra-
tions in female infants born to mothers with PCOS. They showed
that these infants had higher androgen levels than boys or girls
born to mothers who did not have this syndrome. We were unable
to confirm this in our study because we had no data concerning
testosterone levels in mothers and babies. Harriet et al. [24]
compared birth weight in two situations affecting androgen
exposure in utero: complete androgen insensitivity syndrome, in
which the prenatal androgen response is impaired, and congenital
adrenal hyperplasia, in which exposure to prenatal androgen is
increased. They concluded that sex dimorphism in birth size was
unrelated to prenatal androgen exposure. A recent study
measuring the impact of prenatal exposure to high testosterone
levels in sheep [25] found no difference in foetal weight between
males and females.
In conclusion, our results for IVM girls are a matter for concern,
but should be interpreted with caution. We cannot exclude a link
with IVM technology, which may have different impacts on girls
and boys. For example, IVM itself or the maternal serum used in
IVM protocols may have a peri-conceptual effect on gene
methylation, which may be altered in girls but not boys, leading
to foetal programming.
However, it is not yet possible to exclude the possibility of a link
to the underlying infertility of mothers with PCOS. It will
therefore be important to continue following the outcomes of these
infants, focusing, in particular, on girls conceived through IVM, to
determine the potential impact of IVM on their future growth. It is
also important to study the outcomes of girls conceived following
IVM for which the indication was not linked to PCOS.
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